• In recent months, Badger Meter has faced a series of securities class action filings and investigations alleging that the company misled investors about the drivers of its record financial results, demand trends, and growth prospects, including claims that it pulled forward customer orders to recognize revenue early and later reported weaker sales and utility water demand.
• These allegations have drawn in multiple law firms and shareholder groups, raising questions about Badger Meter’s revenue quality, disclosure practices, and the potential impact of pending litigation on the business.
• With these legal challenges intensifying, we’ll assess how alleged revenue pull-forwards and demand misrepresentation could influence Badger Meter’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Badger Meter Investment Narrative Recap

To own Badger Meter, you have to believe in long term demand for smart water infrastructure, recurring software revenues, and disciplined capital allocation. Right now, the key near term catalyst is how the company addresses slowing utility water sales and the upcoming July 22, 2026 earnings release, while the biggest risk is that the mounting class action lawsuits and investigations around alleged revenue pull forwards and demand misrepresentation could weigh on confidence in reported results and management’s credibility.

The Pomerantz LLP class action filing, coming on the heels of Badger Meter’s Q1 2026 miss and a 10% decline in utility water sales, is especially relevant here. It directly links weaker than expected results and the 24% share price drop on April 17, 2026 to alleged misstatements about demand and growth drivers, raising fresh questions about the quality and sustainability of past performance just as investors look to future catalysts like AMI upgrades, software adoption, and SmartCover integration.

Yet behind these growth themes, there is a legal overhang that investors should be aware of, especially if the allegations around...

Badger Meter's narrative projects $1.1 billion revenue and $178.4 million earnings by 2029. This requires 6.8% yearly revenue growth and a roughly $47.8 million earnings increase from $130.6 million today.

Uncover how Badger Meter's forecasts yield a $147.00 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before these allegations, the most optimistic analysts were counting on revenue reaching about US$1.1 billion and earnings of roughly US$186.6 million, but today’s legal and demand questions could push that upbeat view much further away from the more cautious narrative you might have been using.

Explore 6 other fair value estimates on Badger Meter - why the stock might be worth as much as 77% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Badger Meter research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Badger Meter research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Badger Meter's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.